About Morphogenesis
The alarming increase in incidence of chronic disorders worldwide has led to an increased focus on developing ways to repair tissues and organ systems and to eliminate disease rather than just treat symptoms.
Cells fulfill all the qualifications and characteristics of a potential solution because they are the building blocks of tissues and organs. As a bonus, cells are a renewable resource. In order to bring this potential to fruition, great effort is going into the development of technologies to identify, isolate, culture, manipulate and differentiate stem cells because stem cells are arguably the best candidates to treat chronic and in some cases, acute disorders. The list of diseases and injuries cited as potential targets of stem cell therapy is enormous and immediately reveals why stem cells offer so much hope for revolutionary advances in medicine. Many of these aliments, such as Alzheimer's and Parkinson's Disease, diabetes, heart disease, and spinal cord injury, presently have few or no treatment options; so millions suffering from these conditions are currently looking for cures.
Cells can also be used to treat cancer, which is one of the most formidable chronic diseases facing the global community. In fact, in the next 20 years, deaths from cancer are expected to double worldwide. The use of tumor cells coupled with various adjuvants to stimulate the immune system to fight cancer is now a well accepted tool in the fight against cancer. Venturing even further, the potential for an integrated, comprehensive program to detect and eliminate circulating tumor cells such as micro-metastases and minimal residual disease in malignancies is staggering from both social and economic perspectives.
Our Role
Morphogenesis is harnessing the power of cells as tools, technologies and therapies through the development of three major technology/product platforms which are synergistic: the Polymer Antibody Cell Separation (PACS) system, the ImmuneFx cancer immunotherapy and Morphogenesis Allograft Tissue with Compatible HLA (MATCH).
- The MATCH technology will allow the generation of multi-potential stem cell banks with limited and predetermined expression of specific proteins responsible for causing graft acceptance/rejection.
- Because of its extraordinary sensitivity in detecting rare cells, the PACS cell separation system can be used to extract life-saving stem cells for use in combination therapies while simultaneously quantitatively standardizing diagnosis, staging, protocol development, treatment strategy and monitoring in multiple types of cancer.
- This comprehensive cancer management program wouldn't be complete without the innovative new treatment, ImmuneFx. In preclinical studies, ImmuneFx showed an unprecedented 88% long-term survival rate in animals with neuroblastoma, a particularly aggressive type of cancer. In addition, clinical studies in dogs with lymphoma further demonstrated its effectiveness in animals with natural disease.